Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy

Journal of Infectious Diseases

Volumn 204, Issue SUPPL. 3, 2011, Pages

  Marzi, Andrea ^a,b   Ebihara, Hideki ^a,b   Callison, Julie ^a   Groseth, Allison ^a,b   Williams, Kinola J ^b,c,e   Geisbert, Thomas W ^d   Feldmann, Heinz ^a,b,c  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

^d UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^e UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EBOLA VACCINE; UNCLASSIFIED DRUG; VIRAL PROTEIN 40; VIRUS ANTIGEN; VIRUS GLYCOPROTEIN; VIRUS NUCLEOPROTEIN; VIRUS PROTEIN; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; CONFERENCE PAPER; CONTROLLED STUDY; CROSS REACTION; DRUG EFFICACY; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS; FEMALE; GUINEA PIG; HUMAN; HUMAN CELL; IMMUNIZATION; INFECTION PREVENTION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEQUENCE HOMOLOGY; SINGLE DRUG DOSE; VESICULAR STOMATITIS VIRUS; VIRUS NEUTRALIZATION; VIRUS RECOMBINANT; VIRUS STRAIN; WILD TYPE; ZAIRE EBOLAVIRUS;

ANIMALS; ANTIGENS, VIRAL; CERCOPITHECUS AETHIOPS; EBOLA VACCINES; EBOLAVIRUS; FEMALE; GUINEA PIGS; HEK293 CELLS; HEMORRHAGIC FEVER, EBOLA; HUMANS; IMMUNIZATION SCHEDULE; MICE; MICE, INBRED BALB C; PLASMIDS; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VERO CELLS; VESICULOVIRUS;

EID: 80054753979     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir348     Document Type: Conference Paper

References (38)

1. Sanchez A, Geisbert TW, Feldmann H. Filoviridae: Marburg and Ebola viruses. In: Knipe DM, Howley PM, eds: Fields virology. Philadelphia, PA: Lippincott Williams & Wilkins, 2006; 1409-48.
2. Towner JS, Sealy TK, Khristova ML, et al. Newly discovered Ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathog 2008; 4:e1000212.
3. Le Guenno B, Formenty P, Wyers M, Gounon P, Walker F, Boesch C. Isolation and partial characterisation of a new strain of Ebola virus. Lancet 1995; 345:1271-4.
4. Geisbert TW, Jahrling PB, Hanes MA, Zack PM. Association of Ebola-related Reston virus particles and antigen with tissue lesions of monkeys imported to the United States. J Comp Pathol 1992; 106:137-52.
5. Rollin PE, Williams RJ, Bressler DS, et al. Ebola (subtype Reston) virus among quarantined nonhuman primates recently imported from the Philippines to the United States. J Infect Dis 1999; 179:S108-14. (Pubitemid 29091391)
6. Geisbert TW, Bausch DG, Feldmann H. Prospects for immunization against Marburg and Ebola viruses. Rev Med Virol 2010; 20:344-57.
7. Falzarano D, Geisbert TW, Feldmann H. Progress in filovirus vaccine development: Evaluating the potential for clinical use. Expert Rev Vaccines 2011; 10:63-77.
8. Sullivan NJ, Martin JE, Graham BS, Nabel GJ. Correlates of protective immunity for Ebola vaccines: Implications for regulatory approval by the animal rule. Nat Rev Microbiol 2009; 7:393-400.
9. Schnell MJ, Buonocore L, Kretzschmar E, Johnson E, Rose JK. Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles. Proc Natl Acad Sci U S A 1996; 93:11359-65. (Pubitemid 26347126)
10. Garbutt M, Liebscher R, Wahl-Jensen V, et al. Properties of replicationcompetent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol 2004; 78:5458-65. (Pubitemid 38581495)
11. Bente D, Gren J, Strong JE, Feldmann H. Disease modeling for Ebola and Marburg viruses. Dis Model Mech 2009; 2:12-7.
12. Geisbert TW, Daddario-Dicaprio KM, Lewis MG, et al. Vesicular stomatitis virus-based Ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog 2008; 4:e1000225.
13. Feldmann H, Jones SM, Daddario-DiCaprio KM, et al. Effective postexposure treatment of Ebola infection. PLoS Pathog 2007; 3:e2.
14. Geisbert TW, Hensley LE, Geisbert JB, et al. Postexposure treatment of Marburg virus infection. Emerg Infect Dis 2010; 16:1119-22.
15. Geisbert TW, Daddario-DiCaprio KM, Williams KJ, et al. Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J Virol 2008; 82:5664-8. (Pubitemid 351705275)
16. Tuffs A. Experimental vaccine may have saved Hamburg scientist from Ebola fever. BMJ 2009; 338:b1223.
17. Geisbert TW, Geisbert JB, Leung A, et al. Single-injection vaccine protects nonhuman primates against infection with Marburg virus and three species of Ebola virus. J Virol 2009; 83:7296-304.
18. Jones SM, Feldmann H, Stroher U, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 2005; 11:786-90. (Pubitemid 41021212)
19. Hensley LE, Mulangu S, Asiedu C, et al. Demonstration of crossprotective vaccine immunity against an emerging pathogenic Ebolavirus species. PLoS Pathog 2010; 6:e1000904.
20. Connolly BM, Steele KE, Davis KJ, et al. Pathogenesis of experimental Ebola virus infection in guinea pigs. J Infect Dis 1999; 179:S203-17. (Pubitemid 29091404)
21. Bray M, Davis K, Geisbert T, Schmaljohn C, Huggins J. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis 1999; 179:S248-58. (Pubitemid 29091409)
22. Ebihara H, Theriault S, Neumann G, et al. In vitro and in vivo characterization of recombinant Ebola viruses expressing enhanced green fluorescent protein. J Infect Dis 2007; 196:S313-22. (Pubitemid 351417277)
23. Nakayama E, Yokoyama A, Miyamoto H, et al. Enzyme-linked immunosorbent assay for the detection of filovirus species-specific antibodies. Clin Vaccine Immunol 2010; 17:1723-8.
24. Ebihara H, Takada A, Kobasa D, et al. Molecular determinants of Ebola virus virulence in mice. PLoS Pathog 2006; 2(7):e73.
25. Kuhn J. Filoviruses: A compendium of 40 years of epidemiological, clinical, and laboratory studies. In Calisher C, ed. Vienna: Springer- WienNewYork, 2008.
26. Bray M. The role of the Type I interferon response in the resistance of mice to filovirus infection. J Gen Virol 2001; 82:1365-73. (Pubitemid 32519767)
27. Bowen ET, Platt GS, Lloyd G, Raymond RT, Simpson DI. A comparative study of strains of Ebola virus isolated from southern Sudan and northern Zaire in 1976. J Med Virol 1980; 6:129-38.
28. Swenson DL, Wang D, Luo M, et al. Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections. Clin Vaccine Immunol 2008; 15:460-7. (Pubitemid 351967082)
29. Warfield KL, Swenson DL, Olinger GG, Kalina WV, Aman MJ, Bavari S. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis 2007; 196:S430-7. (Pubitemid 351417291)
30. Bukreyev A, Rollin PE, Tate MK, et al. Successful topical respiratory tract immunization of primates against Ebola virus. J Virol 2007; 81:6379-88. (Pubitemid 46878044)
31. Geisbert TW, Pushko P, Anderson K, Smith J, Davis KJ, Jahrling PB. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg Infect Dis 2002; 8:503-7. (Pubitemid 34533328)
32. Sullivan NJ, Geisbert TW, Geisbert JB, et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 2003; 424:681-4. (Pubitemid 36987993)
33. Sullivan NJ, Geisbert TW, Geisbert JB, et al. Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med 2006; 3:e177.
34. Pratt WD, Wang D, Nichols DK, et al. Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector. Clin Vaccine Immunol 2010; 17:572-81.
35. Lichty BD, Power AT, Stojdl DF, Bell JC. Vesicular stomatitis virus: Reinventing the bullet. Trends Mol Med 2004; 10:210-6. (Pubitemid 38581793)
36. Warfield KL, Bosio CM, Welcher BC, et al. Ebola virus-like particles protect from lethal Ebola virus infection. Proc Natl Acad Sci U S A 2003; 100:15889-94. (Pubitemid 38021085)
37. Swenson DL, Warfield KL, Negley DL, Schmaljohn A, Aman MJ, Bavari S. Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. Vaccine 2005; 23:3033-42. (Pubitemid 40462443)
38. Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. Development of a preventive vaccine for Ebola virus infection in primates. Nature 2000; 408:605-9.